NCT01139723

A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I, first-in-human, open label, dose-escalation study of MINT1526A administered alone and in combination with bevacizumab by IV infusion every 3 weeks to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.

Conditions

• Solid Cancers

Interventions

Type	Name	Description
DRUG	MINT1526A	Intravenous escalating dose
DRUG	bevacizumab	Intravenous repeating dose

Timeline

• Start date: 2010-06-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2010-06-08
• Last updated: 2016-11-02

Locations

3 sites across 1 country: United States